Galactomannans for SARS-CoV-2 Infectivity and Viral Load Reduction

Solution Overview

Problem

There are no known treatments that effectively lower the infectivity of SARS-CoV-2, the virus causing COVID-19, which has resulted in significant mortality and transmission.

Innovation Solution

Administering an effective amount of galactomannans or a pharmaceutical composition thereof to subjects to reduce SARS-CoV-2 infectivity, decrease the copy number of SARS-CoV-2 RNA polynucleotides, and increase the cycle threshold (Ct) number of SARS-CoV-2 genes in biological samples.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If no treatment is administered, then the natural course of SARS-CoV-2 infection proceeds, but the infectivity and viral load remain high

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent introduces galactomannans as an intermediary substance that binds to SARS-CoV-2 virions, preventing viral entry into cells and reducing infectivity. This mediator approach directly addresses the technical contradiction by providing a specific therapeutic agent that reduces viral load without causing harmful side effects.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biochemical parameters of the viral infection by introducing galactomannans that alter the interaction between virus and host cells. This parameter change approach enables reduction of infectivity and viral load by modifying the biochemical environment of the infection.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If galactomannans are administered, then SARS-CoV-2 infectivity is reduced, but the complexity of treatment protocols increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs galactomannans as a simple, readily available polysaccharide substance that can be administered without complex delivery systems. This approach reduces treatment protocol complexity by using a straightforward oral supplementation method rather than complex intravenous or injection-based therapies.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Reliability

If galactomannans are administered frequently, then viral load decreases more effectively, but the burden on the subject increases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent applies partial action by recommending specific dosing frequencies and amounts of galactomannans that provide sufficient viral load reduction without excessive administration. This balanced approach maintains effective treatment while minimizing the burden on the subject through reasonable dosing schedules.

Inventive Principle:
Principle #16Partial or excessive action

Data Source

PatentUS20250269014A1Polysaccharides for use in treating SARS-COV-2 infections
Publication Date: 2025.08.28
  • US20250269014A1 patent drawing
  • US20250269014A1 patent drawing
  • US20250269014A1 patent drawing

AI summary

The invention provides a method for treating SARS-CoV-2 by administering an effective amount of galactomannans to a subject in need thereof.